Yaokang biology announced on May 18 that in view of the current rapid development period of the company, there is still investment demand for projects, and it is expected that there will be a large demand for funds for future development. In order to meet the company’s working capital and continuous operation capital demand, ensure the expansion of the company’s business, and take into account the long-term interests of the company and all shareholders, the company plans not to distribute cash dividends, bonus shares or increase share capital with capital reserve in 2021.
The company’s main business is specialized in the R & D, production, sales and related technical services of experimental animal mouse models; In 2021, the company achieved an operating revenue of 394 million yuan, a year-on-year increase of 50.35%; The net profit attributable to the shareholders of the listed company was 125 million yuan, a year-on-year increase of 63.45%. According to the company, in 2022, the company will expand production, strengthen sales capacity, promote R & D investment and talent introduction; In this process, the company needs more funds to ensure the realization of the goal.
